| 1 |
Farooqi R, Kamal A, Thind K, et al. Mycophenolate-induced colitis: 1546[J]. Official Journal of the American College of Gastroenterology, 2018, 113：S889-S890.
|
| 2 |
Milone MC. Chapter 1 - Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring[J]. Personalized Immunosuppression in Transplantation, 2016：1-27.
|
| 3 |
Dhakal P, Gami R, Giri S, et al. Mycophenolate mofetil (MMF)-induced colitis[J]. Blood, 2016, 128：4795.
|
| 4 |
Weigel G, Bertalanffy P, Dubsky P, et al. Mycophenolic acid influences T helper 2 (Th2) cytokine induced expression of intercellular cell adhesion molecule-1 (ICAM-1) on human endothelial cells[J]. Clin Chem Lab Med, 1999, 37(3)：253-257.
|
| 5 |
Dostalek M, Gohh RY, Akhlaghi F, et al. Inosine monophosphate dehydrogenase expression and activity are significantly lower in kidney transplant recipients with diabetes mellitus[J]. Ther Drug Monit, 2013, 35(3)：374-383.
|
| 6 |
Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic acid: An update[J]. Clin Pharmacokinet, 2018, 57(5)：547-558.
|
| 7 |
Božina N, Lalic Z, Nad-Skegro S, et al. Steady-state patients: exploratory analysis of the effects of cyclosporine, recipients′ and donors′ ABCC2 gene variants, and their interactions[J]. Eur J Clin Pharmacol, 2017, 73(9)：1129-1140.
|
| 8 |
Staatz CE, Duffull SB, Kiberd B, et al. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation[J]. Eur J Clin Pharmacol, 2005, 61(7)：507-516.
|
| 9 |
Krenzien F, ElKhal A, Quante M, et al. A rationale for age-adapted immunosuppression in organ transplantation[J]. Transplantation, 2015, 99(11)：2258-2268.
|
| 10 |
Staatz CE, Tett SE. Maximum a posteriori bayesian estimation of mycophenolic acid area under the concentration-time curve: Is this clinically useful for dosage prediction yet？[J]. Clin Pharmacokinet, 2011, 50(12)：759-772.
|
| 11 |
Amelia R, Cossart W, Neil Cottrell, et al. Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients[J]. Transl Androl Urol, 2019, 8(Suppl 2)：S198-S213.
|
| 12 |
Veličković-Radovanović R, Mikov M, Paunović G, et al. Gender diferences in harmacokinetics of tacrolimus and their clinical signifcance in kidney transplant recipients[J]. Gend Med, 2011, 8(1)：23-31.
|
| 13 |
Ana Spasić, Aleksandra Catić-Đorđević, Radmila Veličković-Radovanović. Adverse efects of mycophenolic acid in renal transplant recipients: gender diferences[J]. Int J Clin Pharm, 2019, 41(3)：776-784.
|
| 14 |
Kaplan B, Meier-Kriesche HU, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium[J]. Clin Transplant, 2005, 19(4)：551-558.
|
| 15 |
Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil[J]. Rheumatology (Oxford), 2010, 49(11)：2061-2067.
|
| 16 |
Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics[J]. 2000, 14(3)：179-188.
|
| 17 |
Bunnapradist S, Sampaio MS, Wilkinson AH, et al. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium[J]. Am J Nephrol, 2014, 40(2)：184-190.
|
| 18 |
Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmaco kinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation[J]. Clin Pharmacol Ther, 64(6)：6726-6783.
|
| 19 |
Kolassa N, Stengg R, Turnheim K. Adenosine uptake by the isolated epithelium of guinea pig jejunum[J]. Can J Physiol Pharmacol, 1977, 55(5)：1033-1038.
|
| 20 |
Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity？[J]. Transplant Proc, 2007, 39(1)：88-93.
|
| 21 |
George Liapis, John Boletis, Chrysanthi Skalioti, et al. Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis[J]. Histopathology, 63(5)：649-658.
|
| 22 |
Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetilrelated gastrointestinal mucosal injuryvariable injury patterns，including graft-versus-host disease-like changes[J]. Am J Surg Pathol, 2008, 32(9)：1367-1372.
|
| 23 |
Bunnapradist S, Ambühl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies[J]. Clin Transplant, 2008, 22(6)：815-821.
|
| 24 |
Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: Toxicological and analytical implications[J]. Ther Drug Monit, 2003, 25(1)：1-16.
|
| 25 |
Bailey MJ, Dickinson RG. Acyl glucuronide reactivity in perspective: Biological consequences[J]. Chem Biol Interact, 2003, 145(2)：117-137.
|
| 26 |
Atchison CR, West AB, Balakumaran A, et al. Drug enterocyte adducts: Possible causal factor for diclofenac enteropathy in rats[J]. Gastroenterology, 2000, 119(6)：1537-1547.
|
| 27 |
Qasim M, Rahman H, Ahmed R, et al. Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions[J]. Exp Cell Res, 2014, 322(2)：277-289.
|
| 28 |
Khan N, Asif AR. Transcriptional regulators of claudins in epithelial tight junctions[J]. Mediators Inflamm, 2015：219843.
|
| 29 |
Khan N, Binder L, Pantakani DVK, et al. MPA modulates tight junctions′ permeability via midkine/PI3K pathway in Caco-2 cells: A possible mechanism of leak-flux diarrhea in organ transplanted patients[J]. Front Physiol, 2017, 8：438.
|
| 30 |
杨其顺，杨加彩，王旭，等. 麦考酚酸酯对小鼠肠道γδT淋巴细胞及血浆IL-6、TNF-α表达的影响[J]. 中华器官移植杂志，2018, 39(3)：158-163.
|
| 31 |
Suzuki T, Yoshinaga N, Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium[J]. J Biol Chem, 2011, 286(36)：31263-31271.
|
| 32 |
Kamar N, Faure P, Dupuis E, et al. Villous atrophy induced by mycophenolate mofetil in renal transplant patients[J]. Transpl Int, 2004, 17(8)：463-467.
|
| 33 |
Allison AC, Eugui EM. Mechanism of action of mycophenolate mofetil in preventing acute and chronic allograft rejection[J]. Transplantation, 2005, 80(2 Suppl)：S181-S190.
|
| 34 |
Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea[J]. Transplantation, 2003, 75(5)：665-672.
|
| 35 |
de Andrade LG, Rodrigues MA, Romeiro FG, et al. Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients[J]. Clin Transplant, 2014, 28(11)：1244-1248.
|
| 36 |
Calmet FH, Yarur AJ, Pukazhendhi G, et al. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation[J]. Ann Gastroenterol, 2015, 28(3)：366-373.
|
| 37 |
Selbst MK, Ahrens WA, Robert ME, et al. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil[J]. Mod Pathol, 2009, 22(6)：737-743.
|
| 38 |
von Moos S, Cippà PE, Wüthrich RP, et al. Intestinal infection at onset of mycophenolic acid-associated chronic diarrhea in kidney transplant recipients[J]. Transpl Infect Dis, 2016, 18(5)：721-729.
|
| 39 |
Fernandes MA, Braun HJ, Evason K, et al. De novo inflammatory bowel disease after pediatric kidney or liver transplant[J]. Pediatr Transplant, 2017, 21(1)： 10.1111/petr.12835. |
| 40 |
Roos-Weil D, Ambert-Balay K, Lanternier F, et al. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea[J]. Transplantation, 2011, 92(1)：61-69.
|
| 41 |
Savvidaki E, Papachristou E, Kazakopoulos P, et al. Gastrointestinal disorders after renal transplantation[J]. Transplant Proc, 2014, 46(9)：3183-3186.
|
| 42 |
Di Vico MC, Messina M, Fop F, et al. Recurrent IgA nephropathy after renal transplantation and steroid withdrawal[J]. Clin Transplant, 2018, 32(4)：e13207.
|
| 43 |
Jones-Hughes T, Snowsill T, Haasova M, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model[J]. Health Technol Assess, 2016, 20(62)：1-594.
|
| 44 |
Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and health carecosts in renal recipients[J]. Clin Transplant, 2005, 19(6)：779-784.
|
| 45 |
Bunnapradist S, Ambuhl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies[J]. Clin Transplant, 2008, 22(6)：815-821.
|
| 46 |
Ortega F, Sanchez-Fructuoso A, Cruzado JM, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium[J]. Transplantation, 2011, 92(4)：426-432.
|
| 47 |
Hiramoto LL, Tedesco-Silva H, Medina-Pestana JO, et al. Tolerability of mycophenolate sodium in renal transplant recipients[J]. Int J Clin Pharm, 2018, 40(6)：1548-1558.
|
| 48 |
Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study[J]. Am J Transplant, 2004, 4(2)：237-243.
|
| 49 |
Kamar N, Oufroukhi L, Faure P, et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium[J]. Nephrol Dial Transplant, 2005, 20(10)：2231-2236.
|
| 50 |
Cunningham R, Jones L, Enki DG, et al. Proton pump inhibitor use as a risk factor for Enterobacteriaceal infection: a case-control study[J]. J Hosp Infect, 2018, 100(1)：60-64.
|
| 51 |
Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-aprospective case-controlled study[J]. Am J Transplant, 2009, 9(7)：1650-1656.
|
| 52 |
Maes B, Hadaya K, de Moor B, et al. Severe diarrhea in renal transplant patients: results of the DIDACT study[J]. Am J Transplant, 2006, 6(6)：1466-1472.
|
| 53 |
杨金霞，杨金彩. 益生菌对肠道上皮细胞保护机制的研究进展[J]. 世界华人消化杂志，2015, 23(4): 577-583.
|